Disclaimer: The medications discussed in this article may include compounded preparations from a licensed 503A compounding pharmacy. Compounded medications have not been reviewed or approved by the FDA and are not the same as commercially available FDA-approved products. This content is for educational purposes only and does not constitute medical advice or establish a provider-patient relationship. Please consult a licensed healthcare provider for personalized clinical guidance.
A patient came to me last year after spending three years on a strict calorie-restriction diet. She had lost weight twice and regained it both times. She was convinced her body was broken. When I explained how compounded semaglutide works — and why her previous experience was not a failure of willpower but a failure of biology — she got quiet for a moment. Then she said, “Why did no one ever explain it that way?”
That exchange captures what most patients need before starting any medication: a real explanation of the mechanism, not a sales pitch. The science here is genuinely illuminating, and once patients understand it, the clinical decisions we make together start to make a lot more sense.
Where GLP-1 Comes From and What It Does
GLP-1, or glucagon-like peptide-1, is a hormone produced by enteroendocrine L-cells located in the lining of the small intestine and colon. These cells detect the arrival of nutrients in the gut and release GLP-1 within minutes of a meal. What happens next is a coordinated cascade that involves the pancreas, the brain, and the gastrointestinal tract simultaneously.
One of the most striking findings in metabolic research is how central GLP-1 is to normal insulin release. In healthy subjects, GLP-1 accounts for roughly 50 to 70 percent of the postprandial insulin response — a phenomenon called the incretin effect. After eating, it is not simply high blood sugar that tells the pancreas to release insulin. The gut signals ahead, via GLP-1 and related hormones, before glucose even reaches peak levels in the bloodstream. This anticipatory signaling is elegant and efficient. In many patients with obesity or metabolic dysfunction, this system is blunted, and semaglutide restores the volume of that signal.
A Molecule That Mimics and Amplifies the Natural Signal
Semaglutide is a synthetic GLP-1 analogue, meaning it is a molecule engineered to bind GLP-1 receptors with high affinity and resist the rapid enzymatic breakdown that limits the native hormone’s activity. Natural GLP-1 has a plasma half-life of less than two minutes because an enzyme called DPP-4 degrades it almost immediately. Semaglutide’s molecular structure includes modifications that make it resistant to DPP-4 and allow it to bind to albumin in the bloodstream, extending its half-life to approximately one week. This is why once-weekly dosing is pharmacologically sound.
The pharmacological durability of semaglutide is what transforms a brief gut signal into a sustained therapeutic effect. The molecule is doing something the body’s own GLP-1 cannot: staying active long enough to continuously engage the receptor network.
The Receptor Network: Where in the Body GLP-1 Acts
GLP-1 receptors are not confined to the pancreas. They are distributed across multiple organ systems, and understanding where they are explains most of semaglutide’s clinical effects.
In the gut, GLP-1 receptors are expressed on enteric neurons and smooth muscle, where they modulate motility and gastric emptying. In the peripheral nervous system, receptors are found on vagal afferent neurons in the nodose ganglion, which transmit gut-to-brain signals along the vagus nerve. This pathway carries real-time satiety information from the gastrointestinal tract directly to the brainstem nucleus tractus solitarius, where it is integrated with metabolic signals from other sources. From there, signals ascend to the hypothalamic arcuate nucleus, a region that acts as a master regulator of energy balance and hunger.
The result is what patients describe as “the food noise going quiet.” This is not suppression of hunger through effort. It is a measurable change in the neuroendocrine signals that generate the drive to eat.
How Gastric Emptying Creates Prolonged Satiety
The second major mechanism behind semaglutide’s weight effects is its action on the stomach. Semaglutide increases pyloric tone and reduces antral motility, resulting in a substantial slowing of gastric emptying: food remains in the stomach significantly longer than it would without the drug.
When the stomach empties more slowly, the physical stretch of the gastric wall that signals fullness is maintained for longer. Nutrients enter the small intestine at a slower rate, sustaining the postprandial satiety hormone release that would otherwise peak and drop rapidly. Patients feel full after smaller meals and remain satisfied longer between meals.
This gastric slowing is also the primary source of the nausea that patients experience during early titration — something our practice covers in detail at The Titration Protocol We Changed After Hearing the Same Complaint From Hundreds of Patients.
Blood Sugar Regulation and Insulin Sensitivity
Semaglutide acts directly on pancreatic beta cells, stimulating insulin secretion in a glucose-dependent manner. This means insulin release occurs in response to elevated blood sugar, not continuously — which substantially reduces the risk of hypoglycemia. At the same time, semaglutide suppresses glucagon, the counter-regulatory hormone that raises blood glucose between meals, which stabilizes blood sugar levels throughout the day.
Patients without diabetes frequently ask why they feel less fatigued in the afternoon after starting semaglutide. Part of the answer is weight loss itself. But a significant part is the more stable blood glucose profile the drug produces — the energy crashes associated with reactive hypoglycemia, post-meal glucose spikes, and the hormonal noise of insulin resistance are all reduced.
What the STEP Trials Measured and Why the Numbers Matter
The clinical evidence behind semaglutide is among the strongest in the history of obesity pharmacotherapy. STEP 1, the landmark trial in adults with overweight or obesity without type 2 diabetes, showed a mean body weight reduction of 14.9 percent in the semaglutide group versus 2.4 percent in the placebo group at 68 weeks. Equally important: 86.4 percent of participants in the semaglutide group achieved at least 5 percent weight loss, a threshold widely used as a benchmark for clinically meaningful benefit on metabolic risk factors. In STEP 5, mean weight loss was 15.2 percent at 104 weeks, demonstrating durable effects over two years of continued treatment. Wilding JPH et al. N Engl J Med. 2021
Before these trials, outcomes of this magnitude were associated primarily with bariatric surgery. The mechanism is the same reason: both interventions correct underlying hormonal dysregulation rather than simply asking the patient to exert more effort against a biological system working against them. That patient who called herself “broken” was not broken. Her body was responding predictably to years of dysregulated incretin signaling and appetite hormones.
What Compounded Means and Why It Matters
Patients regularly ask whether compounded semaglutide works differently from the brand-name version. The active pharmaceutical ingredient is the same molecule. The mechanism of action is identical because the molecule is identical. Compounding refers to the process by which a 503A compounding pharmacy formulates the medication — typically in a vial for subcutaneous injection — using the same active ingredient. Importantly, compounded semaglutide has not been reviewed or approved by the FDA as a finished drug product and is not the same as commercially available Ozempic or Wegovy. Our clinical team discusses this distinction with every patient before starting.
The regulatory landscape for compounded semaglutide has evolved since 2024. The shortage-based pathway that allowed broad compounding ended when the FDA declared the shortage resolved in early 2025. What remains available is 503A patient-specific compounding when a licensed prescriber documents a clinical need the commercial product cannot address. For a full explanation, see What I Tell Every Patient Who Asks Whether Compounded Semaglutide Is Real Medication. For a direct comparison with branded Ozempic, see Is Compounded Semaglutide the Same as Ozempic?.
At Precision Telemed, compounded semaglutide is prepared through licensed 503A compounding pharmacies and dispensed through an async telehealth workflow, available in all 50 states.
Who Is a Candidate
The patients who respond best to semaglutide are those who have a meaningful history of weight cycling, difficulty maintaining weight loss through dietary changes alone, or who carry metabolic risk factors such as elevated fasting blood glucose, insulin resistance, or a family history of type 2 diabetes.
Patients who want to understand how semaglutide compares to tirzepatide can read Tirzepatide vs Semaglutide: What I Actually Tell Patients. For guidance on protecting lean muscle mass during weight loss on either medication, see The Protein and Resistance Training Protocol for GLP-1 Patients. And for patients with a cardiovascular history, the SELECT trial changed the evidence base significantly — see What the SELECT Trial Actually Means for Patients Who Are Not Diabetic.
Patients who are pregnant, who have a personal or family history of medullary thyroid carcinoma or MEN2, or who are currently taking certain other medications may not be appropriate candidates. A licensed provider reviews each patient’s history before any medication is started.
FAQ
Q: How quickly does semaglutide start working? Most patients in our practice notice appetite changes within the first two weeks. Weight changes typically become measurable by weeks four to six, with the most significant losses occurring over the first six to twelve months of consistent use.
Q: Is compounded semaglutide the same as brand-name semaglutide? The active pharmaceutical ingredient is the same molecule. The mechanism of action and expected clinical effects are identical. However, compounded semaglutide has not been reviewed or approved by the FDA and is not the same finished drug product as Ozempic or Wegovy. Our clinical team discusses this with every patient.
Q: What are the most common side effects? The most commonly reported side effects are gastrointestinal, including nausea, loose stools, and reduced appetite. These typically occur at dose initiation or escalation and improve over time for most patients. Slow titration significantly reduces their severity.
Q: Can patients stop semaglutide once they reach goal weight? This is a decision made with the treating provider. Clinical data shows that most patients regain approximately two-thirds of their lost weight within one year of stopping semaglutide. Some patients transition to a maintenance dose rather than stopping entirely.
Q: How is Precision Telemed’s semaglutide program structured? The program is fully asynchronous, available in all 50 states, and priced at $149 per month. A licensed provider reviews each patient’s intake and medical history. Medication is fulfilled through a licensed 503A compounding pharmacy. Follow-up care is available through the platform on an ongoing basis.
Q: Does semaglutide work without diet changes? Semaglutide produces weight loss even without formal dietary intervention, as demonstrated in the STEP trials. In practice, patients who make supportive nutritional changes alongside the medication tend to have better outcomes and preserve more lean mass during the weight loss period.
References
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. PubMed
- Rubino DM et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance. JAMA. 2021;325(14):1414-1425. PubMed
- Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87(4):1409-1439. PubMed
- Nauck MA et al. Incretin effects in healthy subjects and patients with type 2 diabetes. Diabetes. 2016;65(6):1490-1495. PubMed
To speak with one of our licensed providers about whether this is right for you, visit precisiontelemed.com.
This article is for educational purposes only and does not constitute medical advice or establish a provider-patient relationship. Compounded medications have not been reviewed by the FDA and are not the same as commercially available FDA-approved products. Please consult your healthcare provider.